CARDIOME PHARMA CORP(NASDAQ:CRME) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $5.91M. Analysts estimated a revenue of $6.73M. Earnings per share were $-0.37. Analysts had estimated an EPS of $-0.19.
In a different note, H.C. Wainwright said it Initiates Coverage on CARDIOME PHARMA CORP, according to a research note issued on Jun 1, 2016. The shares have been rated ‘Buy’ by the firm.
CARDIOME PHARMA CORP (CRME) shares turned negative on Wednesdays trading session with the shares closing down -0.04 points or -1.24% at a volume of 1,21,124. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $3.25. The peak price level was also seen at $3.25 while the days lowest was $3.15. Finally the shares closed at $3.18. The 52-week high of the shares is $10.4 while the 52-week low is $2.95. According to the latest information available, the market cap of the company is $101 M.
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is focused on the development and commercialization of cardiovascular therapies that improve the life and health of patients suffering from heart disease. The Company has two marketed in-hospital cardiology products BRINAVESSTM and AGGRASTAT which are commercially available in markets outside of the United States. BRINAVESSTM (vernakalant (IV)) is approved in the European Union and is registered and approved in approximately 50 countries for the conversion of onset atrial fibrillation to sinus rhythm in adults (for non-surgery patients with atrial fibrillation of seven days or less) and for use in post-cardiac surgery patients with atrial fibrillation of three days or less. AGGRASTAT (tirofiban HCL) is a reversible GP IIb/IIIa inhibitor (an intravenous anti-platelet drug) for use in Acute Coronary Syndrome patients.